Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Bafilomycin A1

Bafilomycin A1
Contact us for more batch information
Select Batch
Purity:98.88%
Resource Download

Bafilomycin A1

Catalog No. T6740Cas No. 88899-55-2
Bafilomycin A1 belongs to the macrolide class of antibiotics and is a V-ATPase inhibitor (IC50=0.44 nM) that is specific and reversible. Bafilomycin A1 is an inhibitor of the late phase of autophagy, blocking the fusion of autophagosomes with lysosomes. Bafilomycin A1 also induces apoptosis.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$287In Stock
5 mg$699In Stock
160 μL x 1 mM (in DMSO)$98In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Bafilomycin A1"

Product Introduction

Bioactivity
Description
Bafilomycin A1 belongs to the macrolide class of antibiotics and is a V-ATPase inhibitor (IC50=0.44 nM) that is specific and reversible. Bafilomycin A1 is an inhibitor of the late phase of autophagy, blocking the fusion of autophagosomes with lysosomes. Bafilomycin A1 also induces apoptosis.
In vitro
METHODS: Human pancreatic cancer cells Capan-1 were treated with Bafilomycin A1 (1-100 nM) for 72 h. Cell growth inhibition was detected using MTT.
RESULTS: Bafilomycin A1 dose-dependently inhibited the growth of Capan-1 cells with an IC50 of 5 nM. [1]
METHODS: Human osteosarcoma cells MG63 were treated with Bafilomycin A1 (1 μmol/L) for 6-24 h. The expression levels of target proteins were detected by Western Blot.
RESULTS: Bafilomycin A1 induced a significant increase in the levels of apoptosis-related proteins p53 and Beclin 1, a significant decrease in the expression of autophagy-related proteins p62 and LC3-I, and an increase in LC3-II. [2]
METHODS: Human hepatocellular carcinoma cells BEL7402 and HepG2 were incubated with Bafilomycin A1 (5 nM) for 24 h, and the cell cycle was examined by Flow Cytometry.
RESULTS: Bafilomycin A1 increased the percentage of BEL7402 and HepG2 cells in the G1 phase of the cell cycle, while cells in the G2/M phase decreased, indicating G1 phase arrest. [3]
In vivo
METHODS: To assay antitumor activity in vivo, Bafilomycin A1 (0.1-1 mg/kg) was intraperitoneally injected once daily for three days into NOD-SCID mice harboring the human acute lymphoblastic leukemia tumor B-ALL.
RESULTS: Bafilomycin A1 prolonged the survival and improved the pathology of xenograft mice by targeting leukemia cells. [4]
METHODS: To investigate the role of autophagy in chronic wound healing, Bafilomycin A1 (1 mg/kg) was administered as a single intraperitoneal injection to diabetic db/db mice.
RESULTS: Bafilomycin A1 treatment significantly accelerated wound healing in db/db mice and exerted a favorable healing effect.Bafilomycin A1 may accelerate the healing of diabetic chronic refractory wounds by promoting cell proliferation, collagen production, and modulating inflammatory homeostasis. [5]
Chemical Properties
Molecular Weight622.83
FormulaC35H58O9
Cas No.88899-55-2
Storage & Solubility Information
Storagestore at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 99 mg/mL (158.95 mM)
H2O: 0.1 mg/mL (0.16 mM)
Solution Preparation Table
DMSO/H2O
1mg5mg10mg50mg
DMSO
1mg5mg10mg50mg
1 mM1.6056 mL8.0279 mL16.0557 mL80.2787 mL
5 mM0.3211 mL1.6056 mL3.2111 mL16.0557 mL
10 mM0.1606 mL0.8028 mL1.6056 mL8.0279 mL
20 mM0.0803 mL0.4014 mL0.8028 mL4.0139 mL
50 mM0.0321 mL0.1606 mL0.3211 mL1.6056 mL
100 mM0.0161 mL0.0803 mL0.1606 mL0.8028 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords